Novocell will use International Stem Cell’s (ISCO) human parthenogenetic stem cell lines for differentiation to human pancreatic islet cells. The studies will be directed by Nikolay Turovets, Ph.D., director, research and therapeutic development at ISCO, in collaboration with Novocell scientists.


Novocell has developed technology to direct embryonic stem cells to become pancreatic islet cells. These have been shown to be effective in treating diabetes in animals, according to the company. The firms hope that the combination of their technologies will result in therapeutic cells with improved immune properties for treatment of diabetes.